Search
Ovid Therapeutics Inc
OVIDAdd to Watchlist
2.690USD
+0.010+0.37%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
449.95MMarket Cap
LossP/E TTM
More Details of Ovid Therapeutics Inc Company
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Ovid Therapeutics Inc Info
Ticker SymbolOVID
Company nameOvid Therapeutics Inc
IPO dateMay 05, 2017
CEOAlexander (Margaret A)
Number of employees23
Security typeOrdinary Share
Fiscal year-endMay 05
Address441 Ninth Avenue, 14Th Floor
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10001
Phone12127764381
Websitehttps://ovidrx.com/
Ticker SymbolOVID
IPO dateMay 05, 2017
CEOAlexander (Margaret A)
Company Executives of Ovid Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
217.58K
+8.08%
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
8.79K
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
217.58K
+8.08%
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
8.79K
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
FAQs
Who are the top five shareholders of Ovid Therapeutics Inc?
The top five shareholders of Ovid Therapeutics Inc are: Dr. Stelios B. Papadopoulos, Ph.D.
How many institutions hold shares of Ovid Therapeutics Inc (OVID)?
As of 2026Q1, 217 institutions hold shares of Ovid Therapeutics Inc, with a combined market value of approximately 67.84M, accounting for 39.21% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 12807224.00.